$CREX

Creative Realities | NT 10-K: Others

This article is a placeholder indicating the filing of an NT 10-K form by Creative Realities. The "NT" designation typically signifies a late filing and that the full 10-K document is pending submission. The content provided is minimal, simply stating "Document".

Original reporting
Published May 1, 2026, 8:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 1, 2026, 9:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CREX
Neutral
medium confidence
Mentioned
$CREX
Relevance
6/10
AlphAI data visualization · based on Moomoo
Decision brief

The 30-second read

$CREXNeutralLow
01

Why it matters

Given the minimal details and low relevance score, the impact on stock price and trading activity is expected to be limited.

02

Market read

The news has low relevance for traders and is unlikely to influence trading decisions significantly.

03

What to watch

The company's overall financial health and recent performance trends could provide additional context not captured here.

Relevance 6/10Timing: low

Background

Creative Realities has filed an NT 10-K, indicating a late or pending filing, which is often a procedural matter.

Company-level read

Ticker impact

$CREXNeutralMedium confidence
Context

The news pertains to Creative Realities' filing status, which has minimal immediate trading impact.

Expected impact

No significant price movement expected in the short term.

Evidence & confidence

As the filing is pending and the news provides minimal details, the impact on stock price is likely negligible, especially given the low relevance score.

Market effects

Limited; the news does not suggest sector-wide changes.

Minimal; no regional effects anticipated.

Negligible; the event is company-specific with no apparent global implications.

Counterpoint

Some traders might interpret the delayed filing as a potential red flag, possibly indicating underlying issues.

Key entities

  • Creative Realities

    A company involved in digital media and technology solutions.

Related articles

$CREXMed

Creative Realities, Inc. Q2 2026 Earnings Call Summary

Creative Realities, Inc. reported Q2 2026 revenue of $21.5M, up 65% YoY, driven by CDM integration and new legacy installations. It said it has realized about 75% of $10M targeted annualized synergies. Net loss more than doubled. The company raised $12M via equity, expects record Q3 revenue and higher ARR from Jan 2027, and margin recovery in 2027.

$CREXMed

Creative Realities Reports Fiscal 2026 Second Quarter Results

CREATIVE REALITIES, INC. (CREX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Creative Realities Reports Fiscal 2026 Second Quarter Results Record Second Quarter Revenue and Improved Outlook as Company Continues Transformation LOUISVILLE, KY – August 13, 2026 – Creative Realities, Inc. (“Creative Realities,” “CRI,” or the

$CREXMedAI 8/10

Creative Realities Announces Pricing of $12 Million Public Offering

Creative Realities, Inc. priced an underwritten public offering of 2,528,571 shares at $3.50 per share and pre-funded warrants for up to 900,000 shares at $3.49 per warrant (plus a $0.01 exercise price). Gross proceeds are expected at about $12.0M. A 30-day option allows the underwriter to buy 428,614 additional shares. Net proceeds will fund working capital, corporate uses, debt paydown, and potential acquisitions; closing expected around June 30, 2026.

$NVDAMed

Nvidia's AI Financing Faces First Big Market Test

Nvidia is financing AI projects, offering $500B in off-balance-sheet guarantees. CEO Jensen Huang aims to fund demand, citing strong interest. Nvidia's revenue hit $216B in FY2024, with $70B in free cash flow. Partners like CoreWeave face credit tightening, with shares down 30%. Nvidia's stock fell 7.6% in October, raising concerns about demand meeting expectations.

$AZNHigh

AZ Combo Extends Lung Cancer Survival

AstraZeneca's Imfinzi and Amgen's Imdelltra combination therapy extended survival by eight months in advanced lung cancer patients, reducing death risk by 58% according to a trial. Side effects were manageable, with 1% experiencing neurological issues. AstraZeneca also reported positive bladder cancer data for Imfinzi plus Pfizer's Padcev. Both studies were presented at an oncology meeting in Madrid.